CY1987A - Protein anti-cancer agent - Google Patents

Protein anti-cancer agent

Info

Publication number
CY1987A
CY1987A CY198797A CY198797A CY1987A CY 1987 A CY1987 A CY 1987A CY 198797 A CY198797 A CY 198797A CY 198797 A CY198797 A CY 198797A CY 1987 A CY1987 A CY 1987A
Authority
CY
Cyprus
Prior art keywords
modified
recognition protein
cell recognition
cancer agent
toxin
Prior art date
Application number
CY198797A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CY1987A publication Critical patent/CY1987A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6829Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY198797A 1989-02-17 1997-09-05 Protein anti-cancer agent CY1987A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31254089A 1989-02-17 1989-02-17
US38909289A 1989-08-03 1989-08-03
US44918789A 1989-12-21 1989-12-21

Publications (1)

Publication Number Publication Date
CY1987A true CY1987A (en) 1997-09-05

Family

ID=27405603

Family Applications (1)

Application Number Title Priority Date Filing Date
CY198797A CY1987A (en) 1989-02-17 1997-09-05 Protein anti-cancer agent

Country Status (18)

Country Link
EP (1) EP0383599B1 (xx)
JP (2) JPH07106159B2 (xx)
KR (1) KR0169729B1 (xx)
AT (1) ATE133993T1 (xx)
AU (1) AU617039B2 (xx)
CA (1) CA2010256C (xx)
CY (1) CY1987A (xx)
DE (1) DE69025211T2 (xx)
DK (1) DK0383599T3 (xx)
ES (1) ES2085329T3 (xx)
FI (1) FI102383B1 (xx)
GR (1) GR3019836T3 (xx)
HK (1) HK15597A (xx)
IE (1) IE71934B1 (xx)
IL (1) IL93425A (xx)
NO (1) NO300595B1 (xx)
NZ (1) NZ232564A (xx)
PT (1) PT93178B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631200B2 (en) * 1989-02-17 1992-11-19 Merck & Co., Inc. Production of modified pe40
JPH0829101B2 (ja) * 1989-04-21 1996-03-27 アメリカ合衆国 組換え抗体―毒素融合タンパク質
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
GB2246779B (en) * 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
AUPM959894A0 (en) * 1994-11-22 1994-12-15 Crc For Biopharmaceutical Research Pty Ltd Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4
WO1998029453A1 (fr) * 1996-12-27 1998-07-09 Mochida Pharmaceutical Co., Ltd. Medicaments diriges vers la membrane cellulaire
AU7553698A (en) * 1997-05-12 1998-12-08 Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Method and construct for inhibition of cell migration
GB0008802D0 (en) * 2000-04-10 2000-05-31 Univ London Molecule
CA2571781C (en) * 2004-06-28 2015-05-12 Yeda Research And Development Co. Ltd Chimeric proteins and uses thereof
CN105766069B (zh) 2013-11-20 2019-04-16 株式会社村田制作所 多层布线基板及具备该多层布线基板的探针卡
WO2017061449A1 (ja) * 2015-10-05 2017-04-13 国立研究開発法人産業技術総合研究所 がん細胞の検出方法、がん細胞内に物質を導入するための試薬、及びがん治療用組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL90047A (en) * 1982-10-19 1992-12-01 Cetus Oncology Corp Cysteine-depleted biologically active muteins other than interferon - '
IE56026B1 (en) * 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
JPH0829101B2 (ja) * 1989-04-21 1996-03-27 アメリカ合衆国 組換え抗体―毒素融合タンパク質

Also Published As

Publication number Publication date
EP0383599B1 (en) 1996-02-07
DE69025211T2 (de) 1996-09-19
IL93425A0 (en) 1990-11-29
GR3019836T3 (en) 1996-08-31
CA2010256A1 (en) 1990-08-17
CA2010256C (en) 2000-07-25
HK15597A (en) 1997-02-14
EP0383599A2 (en) 1990-08-22
NO900758D0 (no) 1990-02-16
PT93178B (pt) 1996-04-30
AU617039B2 (en) 1991-11-14
NO900758L (no) 1990-08-20
PT93178A (pt) 1990-08-31
IE71934B1 (en) 1997-03-12
KR900012626A (ko) 1990-09-01
FI102383B (fi) 1998-11-30
EP0383599A3 (en) 1991-03-27
ES2085329T3 (es) 1996-06-01
AU4994690A (en) 1990-08-23
KR0169729B1 (ko) 1999-01-15
ATE133993T1 (de) 1996-02-15
JPH07106159B2 (ja) 1995-11-15
NZ232564A (en) 1992-08-26
JPH07278200A (ja) 1995-10-24
JP2510846B2 (ja) 1996-06-26
DE69025211D1 (de) 1996-03-21
DK0383599T3 (da) 1996-08-05
NO300595B1 (no) 1997-06-23
IL93425A (en) 1999-08-17
FI900783A0 (fi) 1990-02-16
IE900587L (en) 1990-08-17
FI102383B1 (fi) 1998-11-30
JPH02276590A (ja) 1990-11-13

Similar Documents

Publication Publication Date Title
ATE80166T1 (de) Verfahren zur isolierung rekombinanter polypeptide in biologisch aktiver form.
DE68918867T2 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
EP0157643A3 (en) Antibodies to human interleukin-2 induced by synthetic polypeptides
DE3650751T2 (de) Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung
ATE171216T1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
GR3019836T3 (en) Protein anti-cancer agent
EP0557418A4 (en) A -g(b)-type transforming growth factor
ES2062029T3 (es) Procedimiento de purificacion de proteinas.
ES2109225T3 (es) Anticuerpos, su produccion y uso.
DE69025023T2 (de) Peptide und deren Benutzung
ATE103973T1 (de) Gamma-atriales, natriuretisches polypeptid erkennende monoklonale antikoerper, solche antikoerper produzierende hybridome und deren herstellung und verwendung.
AU6422990A (en) Monoclonal antibody to acetylated lysine residues in recombinant bovine somatotropin